Comparison of high-dose and low-dose corticosteroid therapy for refractory Mycoplasma pneumoniae pneumonia in children

Mycoplasma pneumoniae pneumonia (MPP) is generally a self-limiting disease, but it may become refractory. It is thought that refractory MPP is linked to the excessive immunologic responses of the host. Consequently, the use of adjunctive systemic corticosteroids may have beneficial effects. In this...

Full description

Saved in:
Bibliographic Details
Published in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2019-05, Vol.25 (5), p.346-350
Main Authors: Okumura, Toshihiko, Kawada, Jun-ichi, Tanaka, Masaharu, Narita, Kotaro, Ishiguro, Tomonori, Hirayama, Yuji, Narahara, Sho, Tsuji, Genki, Sugiyama, Yuichiro, Suzuki, Michio, Tsuji, Takeshi, Hoshino, Shin, Nakatochi, Masahiro, Muramatsu, Hideki, Kidokoro, Hiroyuki, Takahashi, Yoshiyuki, Sato, Yoshiaki, Miyajima, Yuji, Uno, Nozomi, Nagai, Noriko, Ando, Shotaro, Sudo, Yuji, Naruse, Kazuhisa, Takahashi, Yuma, Suzui, Ryosuke, Nagata, Yoshihiro, Kawabe, Takashi, Shibata, Motohiro, Shibata, Yusuke, Morishita, Masashi, Kajita, Mitsuharu, Ito, Takuto, Kido, Shinji, Hasegawa, Shinji, Ikeda, Kei, Tokumo, Noriko, Kato, Maki, Kato, Koji, Fukumi, Daichi, Doi, Satoru, Omori, Marei, Watanabe, Nobuhiro, Takada, Hiroyuki
Format: Article
Language:English
Subjects:
Corticosteroids
Mycoplasma pneumoniae pneumonia
Refractory pneumonia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mycoplasma pneumoniae pneumonia (MPP) is generally a self-limiting disease, but it may become refractory. It is thought that refractory MPP is linked to the excessive immunologic responses of the host. Consequently, the use of adjunctive systemic corticosteroids may have beneficial effects. In this study, we compared the effects of high- and low-dose corticosteroid therapy in a pediatric population with refractory MPP. We retrospectively collected data from 91 pediatric MPP patients treated with adjunctive systemic corticosteroids between April 2014 and October 2016. The patients were divided into the following two groups: high-dose corticosteroid group (2 mg/kg/day or more of prednisolone equivalents; n = 38) and low-dose corticosteroid group (
ISSN:1341-321X
1437-7780
DOI:10.1016/j.jiac.2019.01.003